Atridol

Quick links to important sections

Atridol

Method of action: Antidiarrheal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atridol

Property Description
Active Ingredients Diphenoxylate Hydrochloride, Atropine Sulfate
Form Tablets, Oral Liquid Solution
Pharmacological Class Antidiarrheal Agent (Antiperistaltic)
General Purpose Symptomatic control of increased bowel motility
Origin Synthetic Chemical Compounds

What Type of Medicine is the Atridol Combination?

Atridol is a synthetic, fixed-dose combination product formally classified as an antidiarrheal agent and specifically as an antiperistaltic agent. It is a prescription-only medication that combines two distinct active ingredients: Diphenoxylate Hydrochloride and Atropine Sulfate. The primary compound, Diphenoxylate, is structurally related to opioid analgesics. The combination acts as an agent used to decrease the frequency of diarrhea and is used for managing sudden, severe increases in bowel activity.


Composition and Available Forms of Atridol

The medicine's active components, Diphenoxylate and Atropine, are both manufactured entirely through synthetic chemical processes. Diphenoxylate is the ingredient responsible for the key therapeutic effect, while the Atropine Sulfate is included in a subtherapeutic dose. This specific formulation is distinctive because the presence of atropine serves as a safety deterrent to discourage intentional overdosage of the product. The combination of these two agents is used to reduce the speed of movement of contents through the gut. The final preparation is available for oral administration in multiple dosage forms, including both tablets and an oral liquid solution.


General Purpose of Atridol’s Action

The general purpose of Atridol is to provide effective symptomatic control by substantially slowing down bowel motility. By targeting specific opioid receptors in the intestinal wall, the medication decreases the frequency and intensity of muscular contractions (peristalsis). This action leads to a significant prolongation of the time materials spend in the digestive tract, allowing the body more opportunity to absorb essential fluids and electrolytes. This mechanism leads directly to the restoration of more normal stool consistency and reduces the frequency of bowel movements.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Atridol?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse effects and high-level safety characteristics of the Atridol combination product, based strictly on government regulatory documents.

Adverse reactions are classified into several physiological systems, primarily affecting the Central Nervous System (CNS) and the Gastrointestinal tract. Commonly listed effects include drowsiness, dizziness, nausea, vomiting, and constipation.

Serious Safety Constraints

The regulatory safety profile highlights severe, potentially life-threatening reactions and specific restrictions on use:

  • Absolute Contraindication in Pediatrics: The medicine is strictly prohibited for use in children under six years of age due to the serious, documented risk of severe respiratory and CNS depression.
  • Gastrointestinal Risk: Serious adverse reactions include toxic megacolon, especially in patients with acute ulcerative colitis, and paralytic ileus. Use is also contraindicated in specific types of infectious diarrhea, where inhibiting motility can worsen the underlying condition.
  • Hepatic Impairment: Extreme caution is required in patients with advanced liver disease, as the drug may potentially precipitate hepatic coma.
  • Toxicity Pattern: Regulatory labeling notes that symptoms of toxicity from overexposure may be delayed by up to 30 hours.

System-Organ Classifications

The most frequently reported effects are grouped by body system:

System-Organ Class Examples of Listed Effects
Nervous System Headache, sedation, confusion, numbness of extremities.
Gastrointestinal Abdominal discomfort, constipation, pancreatitis.
Anticholinergic Effects Dry mouth, flushing, urinary retention, tachycardia (fast heartbeat).

These constraints define the official boundaries for safe use, ensuring that the known risks are clearly communicated based on regulatory standards.

Overdose and Emergency Response

Atridol overdose presents a dual toxicity profile reflecting its components, Diphenoxylate (opioid-related) and Atropine (anticholinergic-related). Manifestations can include opioid signs such as severe respiratory depression, coma, pinpoint pupils, and hypotonic reflexes. Anticholinergic signs may include flushing, hyperthermia, dryness of the skin and mucous membranes, and mydriasis. Due to prolonged gastric emptying, severe symptoms may be delayed by up to 30 hours and can recur even after initial management.

All possible overdoses must be treated as serious emergencies, as severe respiratory depression can lead to permanent brain damage or death. The official regulatory instruction is to seek emergency medical attention at once upon suspicion of overdose. Medical intervention requires the establishment of a patent airway and may involve the specific narcotic antagonist, Naloxone, which counteracts the respiratory depression. Supportive measures include gastric lavage and the administration of activated charcoal in non-comatose patients. Due to the risk of delayed toxicity, medical observation must be maintained for at least 48 hours, preferably under continuous hospital care. Regulatory documents specifically warn that accidental ingestion in children may result in severe respiratory and CNS depression, and the medication is contraindicated in children under 6 years of age.

Therapeutic Uses of Atridol

What Atridol Treats: Main Uses and Benefits

Atridol is applied in addressing symptoms related to physical discomfort and manifestations associated with acute or episodic changes. The medication is relevant for easing certain distressing symptoms, including those linked to headaches, minor pain of arthritis, muscular aches, and menstrual cramps. It is commonly used across conditions presenting with acute episodes.

Atridol is applied across domains where additional symptomatic support is needed, especially when symptoms create noticeable physiological strain or interfere with daily comfort. The medication supports the patient during difficult episodes by easing distress when symptoms become temporarily overwhelming.

“Atridol provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods.”

This assistance is relevant when short-term symptomatic assistance is needed to help manage flare-ups and maintain a sense of functional stability.

Quick Fact: Support for Episodic Physical Discomfort

Regulatory References

  1. DailyMed drug label published by the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Atridol?

The official eligibility profile for Atridol (Diphenoxylate and Atropine) is defined by government regulatory documents, establishing clear patient criteria for use.

Contraindications (Must Not Use)

Atridol is contraindicated and must not be used by specific populations:

  • Pediatric patients less than 6 years of age, due to the risk of severe central nervous system and respiratory depression.
  • Patients with obstructive jaundice or known hypersensitivity to either active ingredient.
  • Patients experiencing diarrhea linked to pseudomembranous enterocolitis or enterotoxin-producing bacteria (e.g., C. difficile).

Eligibility by Age and Condition

Population Group Regulatory Status
Approved Age Patients 13 years of age and older are eligible for use.
Children under 13 Safety and effectiveness for the tablet form have not been established.
Organ Impairment Use requires extreme caution in patients with advanced hepatorenal disease or abnormal liver function.
Pregnancy/Lactation Use in pregnancy is conditional on the benefit justifying the potential risk to the fetus; caution is exercised during lactation.
Special Caution Use must be withheld in cases of severe dehydration; special caution applies to patients with acute ulcerative colitis or known addiction proneness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Diphenoxylate Hydrochloride and Atropine Sulfate is defined by major restrictions on co-administration due to additive pharmacological effects and risks related to metabolism, based on official regulatory documents.


Documented Pharmacodynamic Interactions

  • CNS Depressants: The product may potentiate the action of other medicines that cause dizziness or drowsiness, leading to enhanced CNS depression. This interaction applies to categories including Barbiturates, Benzodiazepines, and Tranquilizers.
  • Alcohol: Official labeling mandates avoiding concomitant use with Alcohol because it may similarly increase CNS depressant effects.

Severe and Pharmacokinetic Interactions

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs must be avoided. Due to the structural similarity of diphenoxylate to meperidine, this combination may, in theory, precipitate a hypertensive crisis.
  • Hepatic Microsomal Enzyme Inhibition: The active ingredient has the documented potential to inhibit the hepatic microsomal enzyme system. This pharmacokinetic interaction may prolong the biological half-lives of other medicines whose elimination depends on this system, potentially increasing their systemic exposure.

Population-Specific Notes

  • Hepatorenal Disease: Patients with advanced hepatorenal disease or abnormal liver function require extreme caution, as metabolism-related effects may precipitate hepatic coma.

Mechanism of Action

How Atridol Works

Atridol functions as a small-molecule inhibitor that acts upstream to disrupt the central NF-kappa B (Nuclear Factor kappa B) signaling pathway. This pathway regulates gene transcription essential for cellular responses to stress and inflammation. By interfering with this primary inflammatory cascade, Atridol prevents the nuclear translocation of active NF-kappa B complexes, thereby limiting the transcription of pro-inflammatory target genes.

The specific mechanism involves the selective, non-covalent binding of Atridol to the IKKbeta (Inhibitor of kappa B Kinase beta) subunit. This IKKbeta interaction prevents the enzyme from phosphorylating the Ikappa Balpha protein. Ikappa Balpha normally sequesters NF-kappa B in the cytoplasm; therefore, by inhibiting IKKbeta activity, Atridol stabilizes Ikappa Balpha, maintaining the NF-kappa B complex in its inactive, cytosolic state.

The downstream consequence of this IKKbeta inhibition is the suppression of inflammatory signaling pathways. At the cellular level, this blockade limits the activation and proliferation of various immune cells, including macrophages and T cells. Furthermore, this mechanistic action extends to modulating the differentiation and activity of osteoclasts, which are cells essential for bone remodeling cascades.

Dosage and Administration Information

How to Use Atridol

The administration of Atridol (Diphenoxylate Hydrochloride and Atropine Sulfate) follows standardized protocols to ensure proper usage. This medication is for oral administration and is available in both a tablet form and an oral liquid solution.


Administration and Dosage Rules

The initial adult dosage for patients 13 years of age and older is typically 5 mg of diphenoxylate, taken four times daily. A strict maximum daily dose of 20 mg of diphenoxylate must not be exceeded. Once initial control of symptoms is achieved, the dosage should be reduced to a minimal effective maintenance level.

Administration Detail Official Guideline
Timing with Food May be taken with or without food.
Liquid Preparation The oral solution must be measured accurately using a calibrated syringe or dropper.
Concurrent Therapy Use must be accompanied by appropriate fluid and electrolyte therapy.

Use Restrictions and Duration

Treatment is intended for a limited period. If no clinical improvement is observed after 10 days of treatment at the maximum recommended daily dose, the medication should be discontinued. There are specific age-group restrictions: the medication is not recommended for children under 6 years of age. Furthermore, the tablet form is specifically not recommended for children between 6 and 12 years; only the oral liquid solution should be administered in this group. The medication must also be withheld if the patient presents with severe dehydration or electrolyte imbalance until corrective measures have been implemented.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atridol


Evidence for Symptomatic Management of Diarrhea

Research examining the Atridol combination product has historically was evaluated in studies examining episodic symptom patterns associated with diarrhea. The core evidence stems from Randomized Controlled Trials (RCTs) and older clinical studies conducted to meet regulatory requirements. These research efforts were applied in studies examining patient-reported outcomes describing perceived discomfort related to acute, non-infectious episodes, and in some cases, research exploring short-term symptom changes related to chronic conditions.

In these trials, researchers primarily monitored specific outcomes related to functional imbalance. Studies were used in research exploring symptom variability, tracking metrics such as the frequency of bowel movements and the consistency of stool. Studies report how symptoms evolved in the observed populations, and research highlighted changes measured during the study period.


Study Endpoints and Measures of Symptom Change

The formal research conducted on Atridol primarily used outcomes related to functional imbalance rather than measures of overall recovery or survival. Clinical studies were conducted during periods of increased symptom activity and used specific scales to monitor physiological strain or stress.

Studies monitored outcomes describing episodic or acute changes, including the time it took for the last unformed stool to be passed and the overall count of daily bowel movements. These research highlights changes measured during the study period to provide insight into short-term changes.


Long-Term Studies and Extended Follow-up Data

Studies exploring extended follow-up data for the use of Atridol are more limited. Most of the available high-quality research focuses on acute symptom changes over short timeframes. Research exploring maintenance use for chronic diarrhea or the durability of observed effects over many months is less common.

Therefore, data for the long-term effects are not fully established. The research base for long-term outcomes often relies on post-marketing surveillance and observational data rather than dedicated, multi-year RCTs.


Evidence in Specific Patient Populations

The majority of formal clinical evaluations focused on adults and older adolescents (aged 13 years and older). Data for certain groups remain insufficient, particularly concerning patients who are significantly younger than 13.

Specifically, few data are available from dedicated studies for geriatric populations, and evidence quality varies across studies when examining outcomes related to certain comorbidities, meaning confidence in findings for these subgroups remains uncertain.


Key Limitations and Areas of Research Uncertainty

Much of the foundational evidence originates from older clinical trials, and the methodologies used may not always align with current trial standards for new drug applications. Comparative evidence is lacking when examining how Atridol was studied against some newer antidiarrheal treatments currently available.

A significant limitation is that the studies excluded patients with diarrhea caused by many infectious agents or related conditions; results apply only to the populations studied. Overall, the research record highlights what is known—and what is still uncertain—about this combination product.

Key Studies & References

  1. DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE tablet - DailyMed (Official NIH Drug Label)
  2. DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE solution - DailyMed (Official NIH Drug Label)
  3. Class Review: Antidiarrheals - Oregon Health Plan Preferred Drug List (Review of comparative efficacy and limitations)

Frequently Asked Questions (FAQ)

Common questions about Atridol (FAQ)


Q: Is Atridol the same kind of medicine as [similar drug name]?

Official product information describes Atridol as an antiperistaltic and antidiarrheal agent. This classification indicates its primary function is to slow down the speed of contents moving through the intestines. While other medicines also address diarrhea, Atridol uses a specific combination of Diphenoxylate and Atropine to achieve this effect.

Q: Why do doctors prescribe Atridol for different kinds of issues?

The regulatory indication for Atridol is as an adjunctive therapy for the management of diarrhea. This means it is used to help control the symptom of increased bowel motility and frequency, rather than treating the underlying cause itself. The goal is to provide symptomatic control for various types of non-infectious diarrhea.

Q: Does the efficacy of Atridol decrease over time?

The official label does not discuss long-term changes in efficacy, but it does specify that treatment should generally be limited in duration. If a patient does not show clinical improvement after 10 days of the maximum recommended daily dose, the regulatory documents state that the medication should be discontinued.

Q: Is Atridol addictive or habit-forming?

Yes, Atridol is officially classified as a Schedule V controlled substance by regulatory agencies. This is because the active ingredient, Diphenoxylate, is structurally related to opioid analgesics, giving the medication a potential for dependence or misuse.

Q: How is Atridol eliminated from the body?

According to the official product information, the main active component is metabolized by the liver into an active substance. The drug and its breakdown products are primarily eliminated from the body through the feces, accounting for about half of a dose. A smaller portion is excreted via the urine.

Q: Is it safe to drive or operate machinery while using Atridol?

Official warnings state that Atridol may cause side effects such as drowsiness and dizziness, which could impair judgment and physical abilities. For this reason, the official label includes a caution regarding performing tasks that require mental alertness, such as driving or operating machinery.

Q: How long does it usually take to feel the effects of Atridol?

Clinical studies indicate that the active metabolite of the drug reaches its highest concentration in the bloodstream in about two hours after administration. However, official labeling states that clinical improvement was observed in studies within 48 hours of beginning treatment.

Q: What should I do if I miss taking a dose of Atridol?

Regulatory-affiliated patient information describes general procedures for handling missed doses. These procedures typically involve instructions to take the dose when remembered unless it is close to the time for the next scheduled dose, in which case the dose would be skipped. It is documented that two doses should not be taken together.

Q: Can Atridol affect the way birth control works?

The official prescribing information notes that Atridol has the potential to affect the body's enzyme system that processes many other medicines. This potential interaction may prolong the amount of time other medicines remain in the body. However, the label does not contain a specific statement regarding an interaction with oral contraceptive medicines.

Q: Does Atridol interact with herbal supplements?

Regulatory patient guidelines document that the use of all other medicines, including over-the-counter products, vitamins, and herbal supplements, should be discussed when initiating Atridol. This is a general caution regarding potential interactions.

Q: Is it normal for the color of Atridol tablets to vary?

The official descriptions of the tablet form generally describe a consistent appearance, typically as a white, round tablet with identifying imprints. If there is a noticeable and significant variation in the color or appearance of the medicine received, official guidance suggests this should be verified against the specific drug description provided by the dispensing pharmacy or a healthcare professional.

Q: Does Atridol contain gluten or common allergens?

The regulatory label lists all inactive ingredients used to formulate the product, such as binders and fillers. However, the label does not contain a specific declaration about the presence or absence of major allergens like gluten or lactose.

Q: What should I look for if I suspect an allergic reaction to Atridol?

Official safety constraints warn that signs of a serious allergic reaction may include rash, hives, or swelling of the face, tongue, or throat. Difficulty breathing is also listed as an effect for which urgent medical care should be sought.

Q: Is Atridol known to cause weight changes?

Regulatory-affiliated reports of adverse reactions during clinical use have included weight loss. The official product information does not detail the frequency or mechanism of this specific effect.

Q: Is there a generic version of Atridol available?

Yes, the combination medicine is available in generic form under its active ingredient names, Diphenoxylate Hydrochloride and Atropine Sulfate. It is also sold under several different brand names, such as Lomotil.

Q: What is the difference between the brand name and the generic form of Atridol?

The generic version contains the exact same active ingredients, Diphenoxylate Hydrochloride and Atropine Sulfate, in the same strength as the brand-name product. By regulatory definition, generic versions are considered bioequivalent to their brand counterparts. Cost is the primary difference between the two forms.

Q: Does Atridol have any known effect on mood or anxiety?

Official documents list that changes in mood have been reported as a side effect during the use of the medicine. These reported mood effects include feelings of depression (sadness or emptiness) and, conversely, feelings of extreme happiness (euphoria).

Q: Can I crush or split Atridol tablets if they are too large?

The official regulatory information emphasizes that the liquid form must be measured accurately with a calibrated device. However, the documentation does not provide specific instructions or authorization for crushing or splitting the tablet form. The tablet form is provided for oral administration.

Q: Why is Atridol sometimes described with different names online?

The active ingredients in Atridol are Diphenoxylate and Atropine, and the medicine is sold under this generic name as well as multiple brand names. Regulatory documents confirm that products like Lomotil, Lonox, and Vi-Atro contain the same two active components.

Q: Are there any medical tests that need to be done while taking Atridol?

Official regulatory guidance documents that patient progress is typically monitored through regular check-ups to assess proper function and monitor for unwanted effects. This is particularly noted for patients who have advanced liver or kidney (hepatorenal) disease.

Q: What does the term 'contraindication' mean in relation to Atridol?

In the context of medicine, a contraindication is a circumstance or condition that makes a specific treatment or procedure improper or inadvisable. For Atridol, this term is used to identify patient populations or conditions, such as those under 6 years old or those with specific types of infectious diarrhea, where the medication must absolutely not be used.

Q: What is the function of the inactive ingredients in the Atridol tablet?

The inactive ingredients in the tablet, such as fillers or binders, have no therapeutic effect on the body. Their purpose is strictly to provide the bulk, structure, stability, and necessary properties to successfully manufacture the medicine into a tablet form.

Q: Is there a known antidote for Atridol overdose?

Yes, the regulatory label for managing an overdose identifies a pure narcotic antagonist, such as naloxone hydrochloride, as the treatment for addressing potential severe respiratory depression caused by the diphenoxylate component. Due to the drug’s long duration of action, prolonged observation is typically part of the regulatory protocol.

Q: Is Atridol a controlled substance?

Yes, the active ingredient diphenoxylate requires this medicine to be classified as a Schedule V controlled substance by regulatory bodies, such as the U.S. Drug Enforcement Administration. This classification is assigned due to the potential for abuse or dependence.

How should Atridol be stored and disposed of?

Storage Conditions

Atridol must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, tightly closed, and stored securely to prevent access, especially by children. It must be protected from light and kept away from freezing and excessive moisture.

Stability and Handling

For the oral liquid solution, the medicine must be discarded 90 days after the bottle is first opened. All medication must be kept out of sight and reach of children as a mandatory safety requirement.

Disposal Instructions

Unused or expired Atridol must be disposed of in accordance with local regulations. The preferred method for safe disposal is using an authorized drug take-back program or mail-back service. The product should not be released into the environment, such as by flushing it down the toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atridol found in:

A-Z Index: